P142 | ROMIPLOSTIM AS A TREATMENT FOR CHEMOTHERAPY INDUCED THROMBOCYTOPENIA: THREE CASE REPORTS AND A LITERATURE REVIEW

Chemotherapy-induced thrombocytopenia (CIT) is a common hematologic complication of cancer treatment, characterized by decreased platelet counts due to the cytotoxic effects of chemotherapy on megakaryocytes. This condition poses significant clinical challenges, including bleeding risks, treatment delays, and compromised chemotherapy dose intensity. Romiplostim, a thrombopoietin receptor agonist (TPO-RA), has emerged as a promising therapeutic option for CIT management. This paper presents three case reports highlighting the efficacy and challenges associated with romiplostim in treating CIT in breast cancer patients undergoing chemotherapy. Weekly and biweekly administration protocols were evaluated, demonstrating successful platelet recovery, reduced treatment delays, and maintenance of chemotherapy regimens. Additionally, the paper reviews current literature on CIT epidemiology, pathophysiology, and treatment strategies, emphasizing the need for individualized approaches. Romiplostim was shown to be effective in increasing platelet counts, enabling continued chemotherapy while maintaining safety. However, its use in patients with bone marrow infiltration and relapsed thrombocytopenia presents nuanced challenges. These findings underscore the importance of optimizing dosing schedules and integrating romiplostim into personalized CIT management strategies. Future research should focus on controlled trials to refine treatment protocols, lower platelet thresholds for chemotherapy, and explore the long-term safety and efficacy of TPO-RA-based therapies.